Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

CGMP Intracellular Signal cGMP is made from GTP by the enzyme gaunylyl cyclase. Atrial natriuretic peptide and nitric oxide function through this Signal.

Advertisements

JAK-STAT Signaling Pathway.

Chapter 15- Cell Communication Part I- General signaling strategies

Figure 1 Simplified scheme of TGFβ signalling

STAT3 Michael Patel.

The JAK-STAT signaling system represents a series of reactions that take place when a hormone binds a receptor that uses this system. While the hormone.

Leptin receptor functions: When leptin binds to its receptor (LEPR-B) the receptor undergoes a conformational change that activates the receptor-associated.

The JAK-STAT signal-transduction pathway

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Induction of immune tolerance

Laurent L'homme, PhD, David Dombrowicz, PhD

Figure 4 Simplified T cell and antigen presenting

Figure 5 Defects in the JAK–STAT signalling pathway

Figure 3 The cell cycle and the role of CDK4/6 inhibition

Figure 4 C-Terminal protein citrullination catalysed

Figure 1 mTOR pathway activation

Laboratory Practice Guidelines for Detecting and Reporting JAK2 and MPL Mutations in Myeloproliferative Neoplasms Jerald Z. Gong, James R. Cook, Timothy.

Figure 1 Immune cell metabolism during homeostasis

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 7 Defects in apoptosis

Figure 3 Nucleic acid sensors in SLE

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 3 Defects in the T cell receptor signalling pathway

دکتر مجیری داروساز متخصص فارماکولوژی

Figure 2 HGF/c-MET signalling pathway

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

JAK inhibitors in dermatology: The promise of a new drug class

Mechanisms of mast cell signaling in anaphylaxis

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Figure 4 Immune regulatory roles of glycolytic intermediates

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Inflammatory mechanisms in tendinopathy

Figure 4 Mechanisms of leptin function on kidney injury

Figure 3 Inhibitors of the IL-6/JAK/STAT3 signalling pathway

Volume 8, Issue 5, Pages (November 2001)

Figure 1 CD36 structure and post-translational modifications

Nat. Rev. Rheumatol. doi: /nrrheum

Pathogenesis of myeloproliferative neoplasms

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 A model of TNFR–complex I signalling

Signalling links in the liver: Knitting SOCS with fat and inflammation

SOCS Proteins, Regulators of Intracellular Signaling

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

The suppressors of cytokine signaling (SOCS) proteins

Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases Jennifer W. Leiding, MD, Lisa.

Are calcineurin inhibitors-free regimens ready for prime time?

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Signalling downstream of the IL-6 receptor

Fig. 1 BMS binds to the pseudokinase domain of TYK2 and inhibits receptor-mediated TYK2 activation and downstream phosphorylation events in human.

Volume 7, Issue 1, Pages 1-11 (July 1997)

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Overview of molecular JAK signaling.

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.167 Figure 3 JAKs are composed of several key domains including a tyrosine kinase domain, pseudokinase domain, FERM (band four-point-one, ezrin, radixin, moesin) domain, and SH2 (Src homology 2) domain Figure 3 | JAKs are composed of several key domains including a tyrosine kinase domain, pseudokinase domain, FERM (band four-point-one, ezrin, radixin, moesin) domain, and SH2 (Src homology 2) domain. The tyrosine kinase domain binds ATP hydrolysing it to ADP and catalyses both autophosphorylation and other substrates including signal transducers and activators of transcription (STATs). JAK, Janus kinase (JAK) inhibitors (Jakinibs) bind to the pocket ordinarily occupied by ATP, thereby preventing JAKs from using ATP and phosphorylating their substrates. Schwartz, D. M. et al. (2015) Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.167